Clinical Trials Browser

Chondrosarcoma, Extraskeletal Myxoid, Bone Neoplasms, Chondrosarcoma, Hemangioendothelioma, Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT00330564 2024-06-27

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

Phase 2 Terminated

15 enrolled 5 charts

Genitourinary

Carcinoma, Renal Cell, Cysts, von Hippel-Lindau Disease, Neoplasms, Hemangioblastoma

NCT03905889 2024-06-25

A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

Phase 1 Terminated

3 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT05949424 2023-11-29

OPTI-DOSE

Phase 4 Unknown

30 enrolled

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT01517243 2023-09-21

Phase II Study of Alternating Sunitinib and Temsirolimus

Phase 2 Completed

37 enrolled 13 charts

Genitourinary

Carcinoma, Renal Cell

NCT06032728 2023-09-13

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Phase NA Not yet recruiting

488 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT00656669 2023-05-23

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

Phase NA Completed

23 enrolled 12 charts

Breast

Breast Neoplasms

NCT05816642 2023-04-18

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Phase NA Unknown

500 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05751733 2023-03-02

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Phase NA Recruiting

258 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00270413 2022-11-22

SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer

Phase 2 Completed

19 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00520533 2022-10-12

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Phase 1 Terminated

8 enrolled 18 charts

Genitourinary

Carcinoma, Renal Cell, Mycobacterium Infections, Nontuberculous

NCT00981890 2022-10-07

Stereotactic Radiosurgery With Sunitinib for Brain Metastases

Phase 1 Completed

22 enrolled

CNS

Brain Neoplasms

NCT00936832 2022-08-30

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Phase 2 Withdrawn

Gastrointestinal

Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT01061411 2022-08-05

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1 Completed

16 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT01371201 2022-08-04

FIRSTMAPPP

Phase 2 Completed

78 enrolled

CNSEndocrine

Paraganglioma

NCT02450123 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Phase NA Completed

1 enrolled

Other solid neoplasm

Refractory Solid Tumors

NCT02691793 2022-06-15

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Phase 4 Completed

1 enrolled

Other solid neoplasm

Refractory Solid Tumors

NCT03170180 2022-06-15

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Phase 2 Completed

66 enrolled

Gastrointestinal

Stomach Neoplasms

NCT01164202 2022-03-18

SATURNE

Phase 2/3 Completed

78 enrolled 9 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03035630 2022-02-15

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Phase 2 Withdrawn

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02689167 2021-11-29

SURF

Phase 2 Unknown

226 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

Clinical Trials

MOMENTUM-1

TAPUR

THYSU

Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

SUP-R

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Losartan + Sunitinib in Treatment of Osteosarcoma

STROKER

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

CARMENA

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

COPS-01

OCCLURANDOM

Sunitinib and Capecitabine for First Line Colon Cancer

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

SNIPP

ASSET

ImmunoSarc

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

DRUP

OPTI-DOSE

Phase II Study of Alternating Sunitinib and Temsirolimus

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Stereotactic Radiosurgery With Sunitinib for Brain Metastases

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

FIRSTMAPPP

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

SATURNE

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

SURF